Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children?

Antioxidants and Redox Signaling

Volumn 17, Issue 2, 2012, Pages 187-191

  De Giorgis, Tommaso ^a   D'Adamo, Ebe ^a   Giannini, Cosimo ^a   Chiavaroli, Valentina ^a   Scarinci, Antonino ^a   Verrotti, Alberto ^a   Chiarelli, Francesco ^a   Mohn, Angelika ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; MALE; OBESITY; PREPUBERTY; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHILD; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; OBESITY; RECEPTORS, IMMUNOLOGIC;

EID: 84862084482     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4525     Document Type: Article

References (9)

1. Amato M, Montorsi P, Ravani A, Oldani E, Galli S, Ravagnani PM, Tremoli E, and Baldassarre D. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 28: 2094-2101, 2007. (Pubitemid 47517440)
2. Cali AM and Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab 93(11 Suppl 1): S31-S36, 2008.
3. D'Adamo E, Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, and Mohn A. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese pre-pubertal children? Antioxid Redox Signal 14: 1167-1172, 2010.
4. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A, and DavèG. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 43: 511-518, 2007. (Pubitemid 47058227)
5. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, and Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25: 1032-1037, 2005. (Pubitemid 40627851)
6. Giannini C, D'Adamo E, de Giorgis T, Chiavaroli V, Verrotti A, Chiarelli F, and Mohn A. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol 27: 269-275, 2012.
7. Giannini C, de Giorgis T, Scarinci A, Ciampani M, Marcovecchio ML, Chiarelli F, and Mohn A. Obese related effects of inflammatory markers and insulin resistance on increased carotid intima media thickness in pre-pubertal children. Atherosclerosis 197: 448-456, 2008. (Pubitemid 351273267)
8. Koyama H and Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest 40: 623-635, 2010.
9. Schmidt AM, Yan SD, Yan SF, and Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955, 2001. (Pubitemid 32946067)